Hepatoprotective effect of diammonium glycyrrhizinate in the treatment of pulmonary tuberculosis.

OBJECTIVE

To explore the hepatoprotective effect of diammonium glycyrrhizinate (DG) in the treatment of pulmonary tuberculosis.

METHODS

This is a retrospective analysis of clinical data of 113 patients with pulmonary tuberculosis, admitted to The First People's Hospital of Linping District from March 2020 to December 2022. Among them, 55 patients who received conventional anti-tuberculosis treatment (2HRZE/4HR) alone were assigned to the Routine group, while 58 patients who received anti-tuberculosis treatment combined with DG treatment were assigned to the DG group. Treatment efficacy, incidence of liver injury, levels of total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and adverse reactions were assessed in the two groups.

RESULTS

The total efficacy of treatment was significantly higher, and the incidence of liver injury was significantly lower in the DG group compared to the Routine group (<0.05). After the treatment, the levels of TBIL, ALT, and AST in both groups significantly increased, and were significantly lower in the DG group than in the Routine group (<0.05). There was no significant difference in the incidence of adverse reactions between the groups (>0.05).

CONCLUSIONS

In the treatment of pulmonary tuberculosis, combining DG with conventional anti-tuberculosis regimen can improve overall intervention effect, reduce incidence of liver injury, and alleviate its degree.